By
AmyT on
March 22, 2013
The JDRF Capitol Chapter’s 3rd annual Research Summit in Washington, D.C., on March 9 brought out leaders from the Diabetes Community to talk about everything from the latest in research and technological advances to psychosocial issues for kids and adults with diabetes.
More than 600 people attended this year. Among them was one of our good friends, longtime type 1 and fellow D-blogger Scott Strumello, on the scene along with several other familiar faces from…
Read more »
By
WilD on
August 22, 2012
It looks like a duck. It quacks like a … Oh. Wait a minute. It doesn’t quack at all. So why is Abbott Diabetes calling it a duck? (That’s a metaphorical question, just so you know.)
The metaphoric duck we’re talking about lives over in Europe and is quacking along just fine. Its real name is the Abbott Freestyle InsuLinx glucose meter, and it was introduced in Europe in May 2011 and Canada this May,…
Read more »
By
AmyT on
January 17, 2012
In the area of beta cell preservation, there’s a (sort of) new name in the spotlight: Andromeda Biotech, Ltd. with its DiaPep277 treatment. Based in Israel, this company announced last month that phase III clinical trials showed significant preservation of C-peptide levels, a marker for assessing insulin secretion by pancreatic cells. Andromeda joins the ranks of companies like Tolerx and Macrogenics/Lilly, who’ve been vocal about their work to preserve beta cell functioning in newly diagnosed patients…
Read more »
By
AmyT on
November 3, 2010
Why is affordable generic insulin not available to patients in the US? Mainly because the big manufacturers have a stronghold on the patents for this complicated “biologic” drug. But now it seems Big Pharma itself may be presenting a nice alternative.
What I’m talking about is Pfizer’s new attempt to enter the injectable insulin market (less risky than their Exubera flop!) Pfizer and Biocon, a biopharmaceutical company in India, recently announced a multimillion dollar partnership…
Read more »
